AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7% - Here's Why

On Tuesday, AnaptysBio, Inc. (NASDAQ:ANAB) saw its stock price decrease by 5.7%. The stock reached a low of $19.80 before finally closing at $20.02. During the trading session, around 174,378 shares changed hands, which is a significant drop of approximately 85% compared to the average daily trading volume of 1,165,128 shares. The previous day's closing price was $21.22.

Analyst Outlook for AnaptysBio

Despite the drop in stock price, several analysts on Wall Street have expressed optimism about the company's future. For instance, Wedbush reaffirmed an "outperform" rating and established a price target of $40.00 for AnaptysBio's shares. Conversely, JPMorgan Chase & Co. reduced their price target from $66.00 to $36.00 while maintaining an "overweight" rating. Additionally, BTIG Research downgraded the stock from a "buy" to a "neutral" rating. Wells Fargo raised its price target from $40.00 to $51.00 and gave it an "overweight" rating. Guggenheim also adjusted its target from $90.00 to $36.00, assigning a "buy" rating to the stock. Currently, the consensus rating for AnaptysBio is a "Moderate Buy" with an average price target of $37.45 according to MarketBeat.com.

Current Market Conditions

AnaptysBio currently holds a market capitalization of $601.91 million and has a price-to-earnings ratio of -3.25. The company has reported a fifty-day simple moving average of $15.71 and a two-hundred-day simple moving average of $25.54. These market indicators reflect a challenging environment for the stock.

Insider Activities

In related news, Ecor1 Capital, a director at AnaptysBio, acquired 65,184 shares of the company's stock on December 30th, at an average price of $12.92 per share, totaling $842,177.28. This acquisition has increased the director's total holdings to 7,860,180 shares, valued at approximately $101,553,525.60. Notably, insiders hold about 33.70% of the company's stock, indicating their confidence in the firm's strategic direction.

Institutional Investor Movements

Recently, several large institutional investors have adjusted their stakes in AnaptysBio. For example, China Universal Asset Management Co. Ltd. raised its stake by 11.1% during the fourth quarter, now owning 6,452 shares valued at around $85,000. Likewise, Virtus ETF Advisers LLC increased its investment by 24.7%, owning 4,733 shares worth $63,000, and Rhumbline Advisers raised their holdings by 3.8%, bringing their total to 30,077 shares valued at $398,000. Notably, nVerses Capital LLC made a significant jump with a 700% increase, now possessing 1,600 shares after acquiring an additional 1,400 shares. Values First Advisors Inc. also entered the scene with a new stake valued at about $49,000.

Overview of AnaptysBio

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on developing immunology therapeutics. Their product line includes Rosnilimab, targeting PD-1+ T cells to impact autoimmune diseases; ANB032, an antibody preventing activated T cell proliferation; ANB033, targeting IL-15 and IL-2 receptors; ANB101, which modulates plasmacytoid dendritic cells (pDCs); and Imsidolimab, currently in Phase 3 development for generalized pustular psoriasis treatment.

stocks, investment, biotech